AstraZeneca & GlaxoSmithKline: Targets In Cruelty. Customers are key to the survival of Huntingdon Life Sciences. HLS, a global contract research laboratory with sites in England and New Jersey, works with drug companies to conduct their animal experiments. In 2013, AstraZeneca still makes shac.net's Priority Target list, along with GlaxoSmithKline. HLS Files are preserved among Kinship Circle Animal Experimentation Alerts. Learn more about Huntingdon evil and the historic direct-action campaign that fought to end it:

• Bear Witness: HLS Testimonials
• Huntingdon Life Sciences: Caught
• Inside Out: Diary Of Madness
• MOVIE: The Campaign That Changed Everything
• The Talon Conspiracy: Anti-HLS History As Made
• Who Is Huntingdon Life Sciences?
• Mommy's A What?
• Animal Lovers Top FBI Most Wanted?
• About SHAC 7 Prisoners, Will Potter
• Equal Justice Alliance: Repeal Animal Enterprise Terrorism Act
• SHAC North America
• SHAC-UK Global Campaign to Close Down HLS

Pressure On Clients, Financiers, Suppliers.
HLS » Losing Revenue. Revenue continues to fall for Huntingdon Life Sciences, a huge contract animal research lab and subject of multiple investigations over 12 years. HLS has repeat breaches of the U.S. Animal Welfare Act, staff arrests on animal cruelty charges, over 520 infringements of Good Laboratory Practice in England, and a $50,000 payoff to the U.S. Agriculture Department for misstated records and animal welfare violations. Over 12 months HLS loses two major customers and share prices plummet by 75%, from just under $40 to around $8, due in part to global campaigns against HLS shareholders and customers. HLS also loses their top 5 shareholders in 4 months: Barclays, Bank of New York, Mellon and Highbridge Capital. Due to their share price crash, Andrew Baker, Chairman and CEO, even proposes buying out remaining shares at a fixed price of $8.50, to sell to the new Lion Holdings, Inc. As a result, shareholders have filed 2 lawsuits against HLS. 2011: HLS-LSR is still $72 million in debt and published accounts show a revenue decline of 24%. No directors took bonuses last year. Brian Cass cut jobs at UK labs and has said the future looks uncertain. With money debts due by 2011, the floundering lab has yet to secure a loan. Ultimately, HLS needs $60 million to pay off debts, but risks bankruptcy if they lose another customer.

Companies That Dumped HLS During SHAC Campaign.
9/9/08 › Pharma giant Merck KGaA has no plans to be a customer in the future.

7/30/08 › Raymond James-Eagle Asset Management and Old Mutual (Acadian Asset Management) sell off more than 1.5 million HLS-LSR shares in 1 month. Once investors learn the lab that kills an average 500 animals daily in experiments only reliable 5-25% of the time some disassociate completely.

4/08 › We shall not involve ourselves in the transportation of animals worldwide for testing purposes, as an ethical policy, Pakistan International Airways, Salah Uddin, Director. PIA had been involved in beagle transport for research at HLS.

4/9/08 › I can confirm that neither Yorpower, Power Plant Services nor our sister company Techknol Power Generation perform any work on behalf of Huntingdon Life Sciences and the current management have no plans for future dealings with them. YorPower, Guy Phoenix, Director.

12/20/07 › Transamerica Investment, Frontier Capital, SAC Capital, AXA, Wachovia, Alternative Investment Partners and Rathbone Brothers join customers, suppliers, and financiers worldwide that severed ties after learning about habitual falsification of data and animal cruelty.

11/20/07 › Wachovia sells all shares in HLS-LSRI, a research lab cited for animal cruelty, with documentation of technicians who kill dogs by flooding lungs with toxic materials meant for the animals’ stomachs. In one video clip, a lab tech repeatedly punches a screaming 4-month old beagle in the face. During a supposedly post-mortem dissection, a tech slices into the chest of a convulsing monkey.

10/1/07 › Paul Moravek, owner-vice president of Moravek Biochemicals, a radioactive chemical supplier to Huntingdon, states his company will cease business with the lab.

9/20/07 › BNP Paribas, largest shareholder, sells all shares in HLS.

2/7/07 › Customer Surface Logix issues a statement that they'll never again work with HLS, after receiving hundreds of emails, calls and letters from animal advocates.

4/26/06 › HLS is dropped off the Pink Sheets after its sole market maker at the time, The Vertical Group, follows Seaboard in ditching the lab. To whom it may concern: Please be advised that as of April 26, 2006 The Vertical Group has dropped making a market in LSRI. Sincerely, The Vertical Group.

Companies That Dropped Huntingdon In 2005 › Nucryst Pharmaceutical, Johnson and Johnson, Santen, Accent Hansen, Algar, Signcraft, Allport, Archer, Ashtead Plant Hire, Bedfordshire Growers, Brett Martin, British Gypsum, BSS, Bulk Gas, Cambridge Courier Services, Cambridge Plant and Demolition Ltd, Caterfix, CCS Landhaul, Chiltern, Chubb Concrete Company, Cross Country Carriers, Danish Bakery, Data Sciences, David Ball Group, Den Caney Coaches, DG Freight, Dickerson Group, Durapipe, DW Clark, ECR, First Choice Coffee, First Flight Forwarders, Flex-Able Travel, Front Row, Gemmix Ltd, Hamilton Rentals, Hankyu, Hartrodt, Healthcare Logistics, Heathrow Import Clearance, Hewden, Hexagon, House of James, HQ Forklifts, HSS, Huntingdon Plant Hire, Initial City Link, Innaphase, Ipswich Plastics, J Watson Scaffolding, James Latham, JCH Laundry, Johnstones Leyland Decorating Centre, Knights of Old, Labtronics, Laminar Medica, Leapfrog Day Nurseries, Lynn Star, Matthews Transport, MC Freeze, Medifacts, MFI, Network Services, Night Freight, North Yorkshire Timber, Pall-Ex, Planet Same Day Couriers, Plastic Pipe Supplies, Prestons of Potto, Ray Harvey Fish Merchants, RJ Warren, RJJ Worldwide, Scarlet Couriers, SDV, Seko, Simonds Coach and Travel, Smiths Medical, Souters Transport, Speedy Hire, Stan Robinson, Star Transport, Suttons, Trio, United Pallet Network, Vet Diagnostics, Vindon, Whittle Painting, Windsor Engineering, World Precision Instruments, Douglas Brass, Sanderson Transport, D & G Noble, Awad, Cortina, Domestic Securities, Greenville Capital, Management Inc., Royce, Thomson, UBS Global Capital Markets, Vertical Group, Washington Mutual…

Big Pharma Is No Friend To Animals.
Ongoing » Daily Torment. 2006 to 2023: AstraZeneca, headquartered in London, UK, has long worked with contract research organizations like Huntingdon Life Sciences, with its own R&D (Research & Development) centers in over 60 countries. AZ rates among top-10 pharma firms internationally, based upon Rx drug earnings gleaned from animal testing. In 2023 AZ invested about $10.9 billion in R&D, with animal usage fluctuating from 408,000 (2010), 304,751 (2012), and 194,162 (2014)… to 131,615 (2016) and 122,768 (2023). AZ experimentation numbers in the U.S. fail to tally animals excluded from the Animal Welfare Act: rats, mice, birds, and any cold-blooded species (reptiles, amphibians, insects, arachnids, fish). By some accounts, just 5% of animals experimented upon are under supervision of U.S. law. In 2013, the AstraZeneca Beagles gain global notoriety among animal advocates who fight to intercept their fate at experimentation labs. Dogs from a breed-for-research mill in Sweden are transferred to a British AZ breeding compound. With both facilities then terminated, AZ wants surviving beagles sent to its Alderley Park research lab in Cheshire. Activists want to give these dogs a second chance in loving homes. Britain's National Anti-Vivisection Society (NAVS) and Sweden's Animal Rights Alliance step in, as hundreds of beagles are detained at Manchester airport in the UK. AZ ultimately permits employees to rehome 80 beagles, but rejects pleas for the rest of the beagles. The stand-off ends with some 400 dogs sent to AstraZeneca's Cheshire research lab for experimentation and death.

While GlaxoSmithKline (renamed GSK in 2022) animal-usage stats are not easily accessible, the London-based pharmaceutical/biotech company spent roughly $6.2 billion (British pounds) on research and development in 2023. Like AZ, GSK is a top-10 global drug manufacturer with $30.3 billion (approx $38.6 billion U.S. dollars) in 2023 earnings. GSK focal products — respiratory disease and HIV therapies, vaccines… — rely upon animal experimentation for regulatory approval.

Legal Lethargy › Current U.S. and global law mandates animal testing for new pharmaceutical products. This prerequisite is nearly a century old. Regulatory laws have failed to keep pace with modern science. Biotechnology has evolved with cellular, genomic and computational tools. Human-based bioscience means researchers don't need to extrapolate info from animals to people. Guesstimates give way to more predictive science. But “financial investment in human-focused tech generally falls far short of investment in animal experimentation,” (NIH: The Flaws And Human Harms Of Animal Experimentation). Funding is vital to engineer and validate animal-free systems, plus advance models that simulate entire-body function (not just lone cells or organs). Big Pharma itself is best suited to instigate a paradigm shift from animal experimentation to human-relevant research. “Only the pharmaceutical industry has the resources to scientifically validate human-based test methods and steer them through the regulatory framework” (Open Letter To AstraZeneca And Glaxosmithkline Urging Use of Non-Animal Testing Methods To Further Human Health).